Novartis Ag Patent Portfolio Statistics

Novartis Ag

Novartis Ag`s Profile

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Novartis Ag look like?

Total Applications:	7191
Granted Patents:	4879
Grant Index	73.87 %
Abandoned/Rejected Applications:	1726 (26.13%)
In-Process Applications:	583
Average Grant Time:	2.92 Years
Average Office Actions:	1.77

Which Technology Area Novartis Ag is filing most patents in? (Last 10 years)

Art Unit	Definition	Total Applications
1624	Organic Chemistry	459
1626	Organic Chemistry	425
1625	Organic Chemistry	302
1645	Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology	288
1628	Organic Chemistry	215

How many patents are Novartis Ag filing every year?

Year	Total Applications
2022	0*
2021	119*
2020	204
2019	258
2018	371

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Novartis Ag in USPTO?

Publication number: –

Abstract:
None

Publication date: –
Applicant: Novartis Ag
Inventors: Christian Leist

Publication number: US20210393671A1

Abstract:
The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

Publication date: 2021-12-23
Applicant: Novartis Ag
Inventors: Li Zaixing

Publication number: US20210386824A1

Abstract:
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

Publication date: 2021-12-16
Applicant: Novartis Ag
Inventors: Daniels Douglas S

How are Novartis Ag’s applications performing in USPTO?

Application Number	Title	Status	Art Unit	Examiner
17522568	Cell Culture Medium	Application Undergoing Preexam Processing	1653	–
17463391	Pharmaceutical Compositions Of Lipoic Acid Choline Ester Salts And Methods Of Treatment Using Same	Docketed New Case – Ready for Examination	OPAP	Central, Docket
17410307	Nucleic Acids Encoding Fgf21-Fc Fusion Proteins	Docketed New Case – Ready for Examination	OPAP	Central, Docket
17432868	Combination Therapies Of Egfrviii Chimeric Antigen Receptors And Pd-1 Inhibitors	Sent to Classification contractor	OPAP	Central, Docket
17401770	Application Unlock Using A Connected Physical Device And Transfer Of Data Therebetween	Docketed New Case – Ready for Examination	OPAP	Central, Docket